Radiosynthesis and radiotracer properties of a 7-(2-[18f]fluoroethoxy)-6-methoxypyrrolidinylquinazoline for imaging of phosphodiesterase 10a with PET

Pharmaceuticals

Volumn 5, Issue 2, 2012, Pages 169-188

  Funke, Uta ^a   Deuther Conrad, Winnie ^a   Schwan, Gregor ^b   Maisonial, Aurélie ^a   Scheunemann, Matthias ^a   Fischer, Steffen ^a   Hiller, Achim ^a   Briel, Detlef ^b   Brust, Peter ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Fluorine 18; Pde10a; Pet; Positron emission tomography; Quinazoline

Indexed keywords

7 (2 FLUOROETHOXY) 6 METHOXYPYRROLIDINYLQUINAZOLINE F 18; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACCUMULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; ENZYME ASSAY; EX VIVO STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOPHILICITY; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOASSAY;

EID: 84857677917     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph5020169     Document Type: Article

References (43)

1. Beavo, J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 1995, 75, 725-748.
2. Francis, S.H.; Turko, I.V.; Corbin, J.D. Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 2001, 65, 1-52.
3. Keravis, T.; Lugnier, C. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr. Pharm. Des. 2010, 16, 1114-1125.
4. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006, 109, 366-398.
5. Surapisitchat, J.; Beavo, J.A. Phosphodiesterase families. In Transduction Mechanisms in Cellular Signaling: Cell Signaling Collection, 1st ed.; Dennis, E.A., Bradshaw, R.A., Eds.; Academic Press, Elsevier Inc.: San Diego, CA, USA, 2011; pp. 375-380.
6. Bender, A.T.; Beavo, J.A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol. Rev. 2006, 58, 488-520.
7. Fujishige, K.; Kotera, J.; Omori, K. Striatum-and testis-specific phosphodiesterase PDE10A. Isolation and characterization of a rat PDE10A. Eur. J. Biochem. 1999, 266, 1118-1127.
8. Lakics, V.; Karran, E.H.; Boess, F.G. Quantitative comparison of phosphodiesterase Mrna distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59, 367-374.
9. Seeger, T.F.; Bartlett, B.; Coskran, T.M.; Culp, J.S.; James, L.C.; Krull, D.L.; Lanfear, J.; Ryan, A.M.; Schmidt, C.J.; Strick, C.A.; et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003, 985, 113-126.
10. Coskran, T.M.; Morton, D.; Menniti, F.S.; Adamowicz, W.O.; Kleiman, R.J.; Ryan, A.M.; Strick, C.A.; Schmidt, C.J.; Stephenson, D.T. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J. Histochem. Cytochem. 2006, 54, 1205-1213.
11. Xie, Z.; Adamowicz, W.O.; Eldred, W.D.; Jakowski, A.B.; Kleiman, R.J.; Morton, D.G.; Stephenson, D.T.; Strick, C.A.; Williams, R.D.; Menniti, F.S. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 2006, 139, 597-607.
12. Siuciak, J.A.; Chapin, D.S.; Harms, J.F.; Lebel, L.A.; McCarthy, S.A.; Chambers, L.; Shrikhande, A.; Wong, S.; Menniti, F.S.; Schmidt, C.J. Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis. Neuropharmacology 2006, 51, 386-396.
13. Grauer, S.M.; Pulito, V.L.; Navarra, R.L.; Kelly, M.P.; Kelley, C.; Graf, R.; Langen, B.; Logue, S.; Brennan, J.; Jiang, L.; et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J. Pharmacol. Exp. Ther. 2009, 331, 574-590.
14. Siuciak, J.A.; McCarthy, S.A.; Chapin, D.S.; Martin, A.N.; Harms, J.F.; Schmidt, C.J. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background. Neuropharmacology 2008, 54, 417-427.
15. Siuciak, J.A.; McCarthy, S.A.; Chapin, D.S.; Fujiwara, R.A.; James, L.C.; Williams, R.D.; Stock, J.L.; McNeish, J.D.; Strick, C.A.; Menniti, F.S.; et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function. Neuropharmacology 2006, 51, 374-385.
16. O'Connor, V.; Genin, A.; Davis, S.; Karishma, K.K.; Doyère, V.; de Zeeuw, C.I.; Sanger, G.; Hunt, S.P.; Richter-Levin, G.; Mallet, J.; et al. Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific Pde10A phosphodiesterase splice variants. J. Biol. Chem. 2004, 279, 15841-15849.
17. Hu, H.; McCaw, E.A.; Hebb, A.L.O.; Gomez, G.T.; Denovan-Wright, E.M. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur. J. Neurosci. 2004, 20, 3351-3363.
18. Siuciak, J.A. The role of phosphodiesterases in schizophrenia: Therapeutic implications. CNS Drugs 2008, 22, 983-993.
19. Siuciak, J.A.; Strick, C.A. Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia. Expert Opin. Drug Discov. 2007, 2, 1001-1009.
20. Kehler, J.; Ritzén, A.; Greve, D.R. The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin. Ther. Pat. 2007, 17, 147-158.
21. Kehler, J.; Kilburn, J.P. Patented PDE10A inhibitors: Novel compounds since 2007. Expert Opin. Ther. Pat. 2009, 19, 1715-1725.
22. Kehler, J.; Nielsen, J. PDE10A inhibitors: Novel therapeutic drugs for schizophrenia. Curr. Pharm. Des. 2011, 17, 137-150.
23. Tu, Z.; Xu, J.; Jones, L.A.; Li, S.; Mach, R.H. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: Radiosynthesis, in vitro and in vivo evaluation. Nucl. Med. Biol. 2010, 37, 509-516.
24. 11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg. Med. Chem. 2011, 19, 1666-1673.
25. 11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucl. Med. Biol. 2011, 38, 875-884.
26. Verhoest, P.R.; Chapin, D.S.; Corman, M.; Fonseca, K.; Harms, J.F.; Hou, X.; Marr, E.S.; Menniti, F.S.; Nelson, F.; O'Connor, R.; et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J. Med. Chem. 2009, 52, 5188-5196.
27. 18F]JNJ41510417 as a radioligand for positron emission tomography imaging of phosphodiesterase-10A in the brain. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, S236.
28. 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J. Nucl. Med. 2010, 51, 1584-1591.
29. Andrés, J.-I.; de Angelis, M.; Alcázar, J.; Iturrino, L.; Langlois, X.; Dedeurwaerdere, S.; Lenaerts, I.; Vanhoof, G.; Celen, S.; Bormans, G. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J. Med. Chem. 2011, 54, 5820-5835.
30. 18F]JNJ42259152 as potential radioligand for positron emission tomography imaging of phosphodiesterase-10A in the brain. J. Labelled Comp. Radiopharm. 2011, 54, S82.
31. Chappie, T.A.; Humphrey, J.M.; Allen, M.P.; Estep, K.G.; Fox, C.B.; Lebel, L.A.; Liras, S.; Marr, E.S.; Menniti, F.S.; Pandit, J.; et al. Discovery of a Series of 6,7-Dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J. Med. Chem. 2007, 50, 182-185.
32. Nieber, K.; Erdmann, S.; Briel, D.; Schwan, G.; Kubicova, L.; Barbar Asskar, G.; Sträter, N.; Zahn, M.; Brust, P.; Funke, U.; et al. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung. Patent Appl. 00401P0051DE, 20 October 2010.
33. 18F-fluorination of 1,N-disubstituted alkanes as fluoroalkylation agents. J. Labelled Comp. Radiopharm. 1987, 24, 1029-1042.
34. 18F-fluoroalkylation of H-acidic compounds. J. Labelled Comp. Radiopharm. 1988, 25, 201-216.
35. Waterhouse, R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol. 2003, 5, 376-389.
36. OECD (Organisation for Economic Co-operation and Development). Partition coefficient (n-octanol/water), high performance liquid chromatography (HPLC) method. In OECD Guideline for Testing of Chemicals; Paris, France, 2004; pp. 11.
37. Motulsky, H.J.; Christopoulos, A. Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting, 2nd ed.; GraphPad Software, Inc.: San Diego, CA, USA, 2003; pp. 351.
38. Pike, V.W. PET radiotracers: Crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol. Sci. 2009, 30, 431-440.
39. Reinhardt, R.R.; Bondy, C.A. Differential cellular pattern of gene expression for two distinct cGMP-inhibited cyclic nucleotide phosphodiesterases in developing and mature rat brain. Neuroscience 1996, 72, 567-578.
40. Seliskar, M.; Rozman, D. Mammalian cytochromes P450-Importance of tissue specificity. Biochim. Biophys. Acta 2007, 1770, 458-466.
41. 18F]-labelling of aliphatic compounds in high yields via aminopolyether-supported nucleophilic substitution. J. Labelled Comp. Radiopharm. 1986, 23, 467-477.
42. Xing, D.; Chen, P.; Keil, R.; Kilts, C.D.; Shi, B.; Camp, V.M.; Malveaux, G.; Ely, T.; Owens, M.J.; Votaw, J.; et al. Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2b-carbo-1'-fluoro-2-propoxy-3b-(4-chlorophenyl)tropanes: Ligands for the imaging of dopamine transporters by positron emission tomography. J. Med. Chem. 2000, 43, 639-648.
43. Höfgen, N.; Stange, H.; Schindler, R.; Lankau, H.J.; Grunwald, C.; Langen, B.; Egerland, U.; Tremmel, P.; Pangalos, M.N.; Marquis, K.L.; et al. Discovery of imidazo[1,5-a]pyrido[3,2-e] pyrazines as a new class of phosphodiesterase 10A inhibitiors. J. Med. Chem. 2010, 53, 4399-4411.